FLT3 mutations either occur as the more common (∼30% of patients of de novo AML) internal tandem duplication (ITD), an in‐frame duplication, or the less frequent (∼5%–10% of de novo AML) tyrosine kinase domain (TKD) point mutation [4, 5, 6, 7]. The gene discussed is FLT3; the disease is acute myeloid leukemia.